Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | RECQL | P46063 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | BLM | P54132 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | APP | P05067 | 3/20 | 0.46 |
| ▸ | SNCA | P37840 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL12275143 | 0.98 | AURKB (0.60) | AURKBAURKACYP1A2NR4A1MAPT | |
| SCHEMBL29608931 | 0.98 | AURKB (0.64) | AURKBAURKACYP1A2NR4A1MAPT | |
| SCHEMBL156055 | 0.98 | AURKB (0.64) | AURKBAURKACYP1A2NR4A1MAPT | |
| SCHEMBL8508836 | 0.97 | AURKB (0.62) | AURKBAURKACYP1A2NR4A1MAPT | |
| SCHEMBL155097 | 0.97 | AURKB (0.62) | AURKBAURKACYP1A2NR4A1MAPT | |
| SCHEMBL1459623 | 0.88 | NR4A1 (0.57) | AURKBAURKACYP1A2NR4A1MAPT | |
| SCHEMBL29435294 | 0.88 | NR4A1 (0.57) | AURKBAURKACYP1A2NR4A1MAPT | |
| SCHEMBL30683823 | 0.88 | NR4A1 (0.57) | AURKBAURKACYP1A2NR4A1MAPT | |
| Trolamine SCHEMBL11444246 | 0.86 | AURKB (0.55) | AURKBAURKACYP1A2NR4A1MAPT | |
| Hydrochloric Acid SCHEMBL5733553 | 0.86 | AURKB (0.65) | AURKBAURKACYP1A2NR4A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227300-B1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2026-01-28 | — | — | EP | claimed |
| WO-2024120415-A1 | COMPOUNDS TARGETING SSTR2, PREPARATION METHOD THEREFOR, AND USE THEREOF | 烟台蓝纳成生物技术有限公司 | 2024-06-13 | — | — | WO | claimed |
| US-11975079-B2 | Truncated Evans Blue modified fibroblast activation protein inhibitor, preparation method and application thereof | YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD. (CN) | 2024-05-07 | — | — | US | claimed |
| US-20230390421-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-07 | — | — | US | claimed |
| CN-117120428-A | Truncated Evan blue modified fibroblast activation protein inhibitor and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-11-24 | — | — | CN | claimed |
| EP-4227300-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Yantai Lannacheng Biotechnology Co., Ltd. (CN) | 2023-08-16 | — | — | EP | claimed |
| CN-115838393-B | Intermediate for FAPI synthesis and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115838393-A | Intermediate for FAPI synthesis and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-03-24 | — | — | CN | claimed |
| CN-115583989-B | SSTR 2-targeted compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-113429417-B | Method for preparing camptothecin and evans blue coupled amphiphilic compound | 烟台蓝纳成生物技术有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-115583989-A | SSTR 2-targeted compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-01-10 | — | — | CN | claimed |
| CN-115161324-A | Evans blue modified EpCAM-targeted nucleic acid aptamer and preparation method and application thereof | 中国人民解放军空军军医大学 | 2022-10-11 | — | — | CN | claimed |
| CN-113582975-A | Truncated Evans blue modified fibroblast activation protein inhibitor and preparation method and application thereof | 上海蓝纳成生物技术有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-113429417-A | Method for preparing camptothecin and evans blue coupled amphiphilic compound | 上海蓝纳成生物技术有限公司 | 2021-09-24 | — | — | CN | claimed |
| US-20200078478-A1 | Structural molecule of peptide derivative for PSMA-targeting radiotherapy diagnosis and treatment | LI MING HSIN (TW) | 2020-03-12 | — | — | US | claimed |
| EP-4227300-B1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20240285815-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-0621317-B1 | Azo compound and polarizing film using it | MITSUI CHEMICALS INC (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5618868-A | FILM CONTAINS AZO DYE; HYDROTHERMAL RESISTANCE | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-04-08 | — | — | US | disclosed |
| EP-0621317-A1 | Azo compound and polarizing film using it | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1994-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285815-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | FIBP, FAP, ANPEP | AURKB 488/4885AURKA 863/4885CYP1A2 4587/4885 |
| US-20200078478-A1 | Structural molecule of peptide derivative for PSMA-targeting radiotherapy diagnosis and treatment | FOLH1, PSMA1, KLK3 | AURKB 589/4885AURKA 520/4885CYP1A2 4865/4885 |
| US-20230390421-A1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | FIBP, FAP, ANPEP | AURKB 488/4885AURKA 863/4885CYP1A2 4587/4885 |
| US-11975079-B2 | Truncated Evans Blue modified fibroblast activation protein inhibitor, preparation method and application thereof | FIBP, FAP, ANPEP | AURKB 488/4885AURKA 863/4885CYP1A2 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.